Visual field after anti-vascular endothelial growth factor therapy and laser treatment for retinopathy of prematurity
Authors:
- 6 September 2023
- journal article
- research article
- Published by Springer Nature in Graefe's Archive for Clinical and Experimental Ophthalmology
- Vol. 261 (11) , 3207-3213
Abstract
Purpose To evaluate the visual field after anti-vascular endothelial growth factor (VEGF) therapy and laser treatment for retinopathy of prematurity. Method Retrospective cohort study. Infants with retinopathy of prematurity treated by anti-VEGF therapy or laser treatment were included in the study. Degrees of visual field in eight directions examined by Goldmann perimeter (intensity, 1000 apostilb; size, V4e = 64 mm2) were compared between the anti-VEGF therapy and laser treatment groups. The visual acuity (VA) and spherical equivalent refraction were also compared between the two groups. Results Nine eyes with anti-VEGF therapy and 12 eyes with laser treatment were enrolled in the analysis. The total, upper, nasal upper, nasal, nasal lower, temporal lower, and temporal upper visual fields were significantly wider in the eyes with anti-VEGF therapy than in those with laser treatment (496 vs 416, P = .002; 53 vs 45, P = .008; 56 vs 43, P = .003; 58 vs 39, P < .001; 55 vs 44, P = .01; 72 vs 65, P = .01; and 62 vs 56, P = .03, respectively). The logarithm of the minimum angle of resolution VA tended to be better in the eyes with anti-VEGF therapy than in those with laser treatment (0.01 vs 0.15, P = .06). Eyes with anti-VEGF therapy had significantly lower myopia than those with laser treatment (spherical equivalent refraction: -0.72 vs -5.7, P = .001). Conclusion Anti-VEGF therapy may provide a wider visual field, better VA, and less myopia compared with laser treatment.Keywords
This publication has 24 references indexed in Scilit:
- A Systematic Review and Meta-Analysis on the Safety of Vascular Endothelial Growth Factor (VEGF) Inhibitors for the Treatment of Retinopathy of PrematurityPLOS ONE, 2015
- Refractive Outcomes Following Bevacizumab Monotherapy Compared With Conventional Laser TreatmentJAMA Ophthalmology, 2014
- Fluorescein angiographic observations of peripheral retinal vessel growth in infants after intravitreal injection of bevacizumab as sole therapy for zone I and posterior zone II retinopathy of prematurityBritish Journal of Ophthalmology, 2014
- Exudative retinopathy and detachment: A late reactivation of retinopathy of prematurity after intravitreal bevacizumabJournal of American Association for Pediatric Ophthalmology and Strabismus, 2013
- Progression of myopia and high myopia in the Early Treatment for Retinopathy of Prematurity Study: Findings at 4 to 6 years of ageJournal of American Association for Pediatric Ophthalmology and Strabismus, 2013
- Efficacy of Intravitreal Bevacizumab for Stage 3+ Retinopathy of PrematurityNew England Journal of Medicine, 2011
- Progression of Myopia and High Myopia in the Early Treatment for Retinopathy of Prematurity StudyOphthalmology, 2008
- Retinopathy of prematurity: A global perspective of the epidemics, population of babies at risk and implications for controlEarly Human Development, 2008
- The International Classification of Retinopathy of Prematurity RevisitedArchives of Ophthalmology (1950), 2005
- Revised Indications for the Treatment of Retinopathy of PrematurityArchives of Ophthalmology (1950), 2003